Skip to main content
Alethia Young

Alethia Young

Chief Financial Officer, Bicycle Therapeutics
Ms. Young has over 20 years of experience in biopharmaceutical industry. Currently, Ms. Young is the chief financial officer at Bicycle Therapeutics. In this role, Ms. Young oversees the company’s finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy. She also serves on the board of directors for PTC Therapeutics and Pacira Biosciences. Previously Ms. Young served as chief financial officer at Graphite Bio, senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering large cap and small-mid-cap biotechnology companies. Prior to joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions. Ms. Young earned a B.A. in Economics and Spanish from Duke University. She currently serves on the board of directors for BUILD NYC.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.